Philanthropic support for HIV/AIDS initiatives in low- and middle-income countries totaled $618 million in 2014, up 8 percent from 2013, a report from Funders Concerned About AIDS finds.
According to the report, Philanthropic Support to Address HIV/AIDS in 2014 (32 pages, PDF or HTML), the increase in funding — which followed an 8 percent drop in 2013 — was driven by the top two funders, the Bill & Melinda Gates Foundation (up $14.9 million, to nearly $224 million) and Gilead Sciences (up $46.6 million, to $73.4 million), and was mostly directed to efforts in the United States, making the U.S. the top recipient country of private funding, with a total of $139 million. In addition, the report found that philanthropic funding for HIV/AIDS remained concentrated among the top donors, with the top twenty funders, which includes the M.A.C AIDS Fund, Wellcome Trust, and the Ford Foundation, accounting for 81 percent of total grant dollars awarded. FCAA executive director John L. Barnes noted, however, that despite "the overall increase, private philanthropic funding for HIV/AIDS is still down 8 percent from the high-water mark set in 2008 ($674 million), even at the height of the global economic crisis."
The report also found that a significant portion of the funding ($262 million) went to grants with a global, non-country-specific geographic focus and that the top intended use of those grants was research of worldwide benefit ($215 million), followed by prevention ($142 million), treatment ($134 million), advocacy ($93 million), and social services ($76 million). In addition, half of all country-level funding ($177 million) went to high-income countries, while just over a third ($125 million) went to middle-income countries.
According to UNAIDS, in order to make significant progress toward ending the epidemic in low-and middle-income countries by 2030, a 76 percent increase in HIV/AIDS funding — from the $20.2 billion invested in 2014 (of which philanthropic funding accounted for $438.5 million) to $35.6 billion — is needed by 2020.
"We hope that funders, stakeholders, and grantees will find the new grant-level data to be a valuable tool to reestablish urgency in the philanthropic response to HIV/AIDS, and to build on evidence-based strategies that target those most in need in the places most impacted," said Barnes. "We hope that in 2020 we can look back to the small increase reported in 2014 as the first in a series of steadily increasing steps toward meeting the ambitious goal of ending HIV/AIDS."